EORTC study of non-Hodgkin's lymphoma: Phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma
| Autor: | D Bron, J. Thomas, Umberto Tirelli, Riet Somers, Nicole Duez, C De Wolf-Peeters, J. J. Keunig, Patrice Carde, M. van Glabbeke, Alain Delmer, R. De bock |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Leucovorin Gastroenterology Extranodal Disease Bleomycin Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Life Tables Mechlorethamine Stage (cooking) Cyclophosphamide Survival analysis Aged Etoposide Neoplasm Staging Teniposide Chemotherapy Performance status business.industry Lymphoma Non-Hodgkin Remission Induction Hematology Middle Aged medicine.disease Combined Modality Therapy Survival Analysis Thrombocytopenia Surgery Non-Hodgkin's lymphoma Lymphoma Radiation therapy Methotrexate Treatment Outcome Oncology Doxorubicin Vincristine Procarbazine Prednisone Female business |
| Zdroj: | Europe PubMed Central |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/5.suppl_2.s85 |
| Popis: | Summary In the EORTC lymphoma cooperative group, a randomized phase HI study was done for patients with stage II, III, IV intermediate- and high-grade lymphoma. Eight courses of CHVmP-VB were compared to eight courses of ProMACE-MOPP. Response was evaluated after 8 courses. Of 430 patients entered, 346 were eligible for this first analysis. Additional radiotherapy was given at initial large masses or residual disease after three courses. Response rate was higher in the CHVmP-VB arm in comparison to the ProMACE-MOPP arm, 82% vs. 65% (p > 0. 0005). In the ProMACE-MOPP arm, treatment had to be interrupted because of patient refusal in 7% of the patients. So far there has been no significant difference in freedom from progression at 5 years (49% vs. 47%), relapse-free survival (59% vs. 59%), or overall survival (55% vs. 49%). Patients with early response at 4 courses showed no better RFS in comparison with late responders between 4 and 8 courses. The International Index, based on age, stage, SLDH, performance status, and number of extranodal localizations showed a good prognostic significance in this series of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|